Publications

Investigational new drugs

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

01-10-2015

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.

01-10-2015

Veterinary and comparative oncology

Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.

01-09-2015

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

15-08-2015

Clinical breast cancer

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

01-08-2015

British journal of clinical pharmacology

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

01-08-2015

Clinical pharmacokinetics

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

01-08-2015

British journal of cancer

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

28-07-2015

CPT: pharmacometrics & systems pharmacology

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

01-07-2015

Pharmaceutical research

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

01-07-2015

Clinical lung cancer

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

01-07-2015

CPT: pharmacometrics & systems pharmacology

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

01-07-2015

Journal of pharmaceutical and biomedical analysis

Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.

10-06-2015

Veterinary and comparative oncology

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

01-06-2015

Cancer treatment reviews

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

01-05-2015

Pigment cell & melanoma research

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

01-05-2015

British journal of clinical pharmacology

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

01-05-2015

BioMed research international

Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy".

30-04-2015

British journal of cancer

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.

14-04-2015

Bioanalysis

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

01-04-2015

Journal of pharmaceutical and biomedical analysis

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

25-03-2015

Pharmacology research & perspectives

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

01-03-2015

European journal of clinical pharmacology

Baclofen overdose treated with continuous venovenous hemofiltration.

01-03-2015

International journal of pharmaceutics

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

01-02-2015

Investigational new drugs

Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

01-02-2015

Investigational new drugs

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

01-02-2015

Oncoscience

P-gp and taxanes.

17-01-2015

International journal of cancer

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.

01-01-2015

Antimicrobial agents and chemotherapy

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

01-01-2015

Pharmaceutical research

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

01-01-2015

Bioanalysis

Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.

23-12-2014

Bioanalysis

Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.

17-12-2014

Investigational new drugs

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

01-12-2014

Pediatric blood & cancer

Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation.

01-12-2014

Nature communications

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response.

12-11-2014

British journal of cancer

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.

28-10-2014

Human gene therapy methods

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

01-10-2014

Drugs & aging

Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.

01-10-2014

Investigational new drugs

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.

01-10-2014

Annals of oncology : official journal of the European Society for Medical Oncology

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

01-10-2014

Bioanalysis

Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review.

01-09-2014

Nederlands tijdschrift voor geneeskunde

[Hyperglycaemia during treatment with everolimus].

15-08-2014

European journal of cancer (Oxford, England : 1990)

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

01-08-2014

European journal of cancer (Oxford, England : 1990)

Therapeutic drug monitoring in cancer--are we missing a trick?

01-08-2014

European journal of cancer (Oxford, England : 1990)

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

01-08-2014

Breast cancer research and treatment

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

01-07-2014

Clinical cancer research : an official journal of the American Association for Cancer Research

P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.

15-06-2014

Therapeutic drug monitoring

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.

01-06-2014

British journal of cancer

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.

27-05-2014

Clinical cancer research : an official journal of the American Association for Cancer Research

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

15-05-2014

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.

Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Corrigendum to "Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy".

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.

Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells.

Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Baclofen overdose treated with continuous venovenous hemofiltration.

Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.

Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

P-gp and taxanes.

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).

Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.

Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.

"Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".

Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation.

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response.

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.

Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.

Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error.

Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.

Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review.

[Hyperglycaemia during treatment with everolimus].

Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

Therapeutic drug monitoring in cancer--are we missing a trick?

Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.

Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.

Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

This site uses cookies